Alkylating Compound Pathogen Inactivation with Solid-Phase Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for pathogen inactivation lack universality and specificity, particularly in biologics and medical devices, due to residual toxicity from alkylating compounds and interference with protein functions.
Innovation Solution
The use of alkylating compounds with two or more aziridinyl groups connected by polyamine constructs, which selectively bind to nucleic acids, combined with a solid-phase agent or neutralizing compounds to eliminate residual toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If alkylating compounds are used for pathogen inactivation, then pathogen inactivation efficiency is improved, but residual toxicity increases
Solution Approach 1:
A solid-phase agent is introduced as an intermediary substance that selectively binds to and removes residual alkylating compounds from the treated sample. The solid-phase agent acts as a mediator between the alkylating compound and the biologics, capturing the harmful residual agent while allowing the biologics to pass through unaffected, thereby resolving the contradiction between pathogen inactivation efficiency and residual toxicity
Solution Approach 2:
The invention changes the physical state and binding parameters of the alkylating compound by introducing a solid-phase agent with specific binding affinity. This parameter change allows the residual alkylating compound to be selectively captured and removed from solution, transforming it from a harmful residual substance into a bound state that can be easily separated, thus reducing residual toxicity while maintaining inactivation efficiency
2Adaptability or versatility
If broad-spectrum antimicrobials are used, then universality against pathogens is improved, but specificity toward biologics deteriorates
Solution Approach 1:
The solid-phase agent serves as a selective intermediary that discriminates between the alkylating compound and biologics based on their different chemical properties. It binds specifically to the alkylating compound through electrostatic or hydrophobic interactions while leaving biologics untouched, thereby enabling broad-spectrum pathogen inactivation without compromising biologics integrity
Solution Approach 2:
The invention applies local quality by creating different chemical environments for different substances in the same treatment system. The solid-phase agent provides a localized binding site with specific chemical properties that selectively interact with alkylating compounds, while the bulk solution maintains conditions suitable for biologics, thus achieving both universality and specificity
3Reliability
If reactive antimicrobial compounds are used, then pathogen inactivation capability is improved, but interference with protein functions increases
Solution Approach 1:
The solid-phase agent acts as a protective intermediary that captures reactive alkylating compounds before they can interact with biologics proteins. By providing an alternative binding target with higher affinity, it prevents the alkylating compound from causing harmful modifications to protein functions, thus maintaining inactivation capability while eliminating protein interference
Solution Approach 2:
The invention applies preliminary action by removing residual alkylating compounds through the solid-phase agent before the treated sample is used or stored. This preliminary removal step ensures that no reactive compounds remain to interfere with subsequent protein functions or applications, thereby preserving both inactivation effectiveness and protein integrity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves high-efficiency pathogen inactivation with minimal impact on proteins and reduces residual toxicity, making it suitable for a wide range of applications including biologics and medical devices.
Implementation Method 1
compounds with two or more aziridinyl groups, interconnected through polyamine constructs, that have high and selective affinity to nucleic acids
Implementation Method 2
The residual compound may be removed from the sample by treatment with a solid phase agent that removes, or otherwise reacts with, the compound
Data Source
AI summary
The invention provides a method for inactivation or reduction of pathogens, microorganisms or parasites in a sample, media, composition, utility, device, surface or organism by treatment with an alkylating compound of Structure I, followed by elimination or reduction of the residual compound with Structure I by treatment with a neutralizing agent, which eliminates or reduces the toxicity or other undesirable properties of the alkylating compound with Structure I. The neutralizing agent may be present in a treatment solution or be part of a solid-phase agent, and preferably acts by eliminating the alkylating properties of the compound of Structure I.